Amy D DiVasta1, Marc R Laufer. 1. Division of Adolescent and Young Adult Medicine, Boston Children's Hospital, Boston, Massachusetts 02115, USA. amy.divasta@childrens.harvard.edu
Abstract
PURPOSE OF REVIEW: Endometriosis is increasingly being recognized and diagnosed in adolescents. As a result of this earlier diagnosis, treatment with agents like gonadotropin releasing hormone agonist (GnRHa) begins earlier and may last longer. Long-term effects of GnRHa treatment for endometriosis are of concern when treating adolescents. RECENT FINDINGS: GnRHas are used for adolescents with surgically confirmed endometriosis. GnRHa treatment is effective for pain reduction, but is associated with menopausal symptoms and decreases in bone density. Different regimens of hormonal add-back therapy have been studied in adults to attempt to prevent these side-effects. SUMMARY: GnRHa therapy is a highly effective, nonsurgical treatment option for many adolescents with endometriosis, but is accompanied by side-effects of bone loss and menopausal symptoms. Side-effects may be decreased by introducing appropriate add-back therapy. Monitoring of bone density by DXA is recommended for prolonged use of GnRHa in adolescents.
PURPOSE OF REVIEW: Endometriosis is increasingly being recognized and diagnosed in adolescents. As a result of this earlier diagnosis, treatment with agents like gonadotropin releasing hormone agonist (GnRHa) begins earlier and may last longer. Long-term effects of GnRHa treatment for endometriosis are of concern when treating adolescents. RECENT FINDINGS: GnRHas are used for adolescents with surgically confirmed endometriosis. GnRHa treatment is effective for pain reduction, but is associated with menopausal symptoms and decreases in bone density. Different regimens of hormonal add-back therapy have been studied in adults to attempt to prevent these side-effects. SUMMARY: GnRHa therapy is a highly effective, nonsurgical treatment option for many adolescents with endometriosis, but is accompanied by side-effects of bone loss and menopausal symptoms. Side-effects may be decreased by introducing appropriate add-back therapy. Monitoring of bone density by DXA is recommended for prolonged use of GnRHa in adolescents.
Authors: Jenny Sadler Gallagher; Henry A Feldman; Natalie A Stokes; Marc R Laufer; Mark D Hornstein; Catherine M Gordon; Amy D DiVasta Journal: J Pediatr Adolesc Gynecol Date: 2016-02-27 Impact factor: 1.814
Authors: Jenny Sadler Gallagher; Stacey A Missmer; Mark D Hornstein; Marc R Laufer; Catherine M Gordon; Amy D DiVasta Journal: J Pediatr Adolesc Gynecol Date: 2018-03-15 Impact factor: 1.814
Authors: Adam J Davenport; Ioana Neagoe; Nico Bräuer; Markus Koch; Andrea Rotgeri; Jens Nagel; Alexis Laux-Biehlmann; Frederic Machet; Anne-Marie Coelho; Susan Boyce; Nikisha Carty; Mark J Gemkow; Stephen D Hess; Thomas M Zollner; Oliver M Fischer Journal: Sci Rep Date: 2021-10-06 Impact factor: 4.379
Authors: Giovanni Grandi; Angela Toss; Laura Cortesi; Laura Botticelli; Annibale Volpe; Angelo Cagnacci Journal: Biomed Res Int Date: 2015-08-30 Impact factor: 3.411